Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ray Gani
Observed names:
R Gani,
R. Gani
Observed institutions:
IQVIA (United Kingdom),
IQVIA (United States),
Boehringer Ingelheim (United Kingdom)
ORCID:
0000-0002-2967-3132
Observed ORCID:
0000-0002-2967-3132
OpenAlex ID:
A5018722015
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
2012
·
Anuraag R Kansal
, Sonja V Sorensen
, et al.
·
Heart
·
127
PDF
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
2008
·
Ray Gani
, Gavin Giovannoni
, et al.
·
PharmacoEconomics
·
101
The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies
2020
·
Chiara Azzari
, Vincenzo Baldo
, et al.
·
ClinicoEconomics and Outcomes Research
·
28
PDF
Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium
2012
·
Robert Hettle
, Hanne Wouters
, et al.
·
Respiratory Medicine
·
25
Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
2022
·
Jesús Ruiz-Aragón
, Sergio Márquez-Peláez
, et al.
·
Vaccines
·
22
Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD
2010
·
Ray Gani
, Jane Griffin
, et al.
·
Primary Care Respiratory Journal
·
22
PDF
Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain
2020
·
Jesús Ruiz-Aragón
, Ray Gani
, et al.
·
Human Vaccines & Immunotherapeutics
·
21
PDF
Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland
2021
·
Ulrich Heininger
, Matthew Pillsbury
, et al.
·
The Pediatric Infectious Disease Journal
·
17
An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
2022
·
Anna Fochesato
, Sara Sottile
, et al.
·
Vaccines
·
14
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
2018
·
Huan Huang
, Kelly F Bell
, et al.
·
PubMed
·
14
Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis
2007
·
Ray Gani
, Richard M Nixon
, et al.
·
Journal of Medical Economics
·
10
PDF
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
2023
·
Peter Gal
, Gyorgyi Feldmajer
, et al.
·
PharmacoEconomics
·
3
PDF
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia
2025
·
Asher Chanan-Khan
, Kirollos Hanna
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
2
Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget
2023
·
Ritika Kapoor
, Baudouin Standaert
, et al.
·
Vaccines
·
2
PDF
Pnd13 a Cost-effectiveness Analysis of Natalizumab Vs. Interferon-beta and Glatiramer Acetate in Patients With Active Relapsing-remitting Multiple Sclerosis Currently Failing on Existing Therapy
2008
·
R Gani
, ER Samuels
, et al.
·
Value in Health
·
2
Pss24 - Estimation of the Long-term Population Costs and Benefits for Five Different Varicella Childhood Immunization Strategies in Bulgaria
2018
·
M. Dimitrova
, M.M. Zdrakova
, et al.
·
Value in Health
·
1
PDF
Msr228 Value-based Decision Boundaries Analysis (vb-dba): a Novel Method of Integrating Network Meta-analysis and Cost-effectiveness Modelling to Estimate Pricing Thresholds Based on Target Product Profiles
2026
·
Abhirup Dutta Majumdar
, Sekhar K. Dutta
, et al.
·
Value in Health
Hpr27 Evidence Generation Recommendations to Support Global Pharmaceutical Launches Following Major Policy Changes in the Us (inflation Reduction Act and Most Favored Nation) and Eu (joint Clinical Assessments)
2026
·
Md Sohail Aman
, Chetna Demla
, et al.
·
Value in Health
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
2025
·
Peter Gal
, Gyorgyi Feldmajer
, et al.
·
PharmacoEconomics
Reply to letter from Alvarez et al.
2020
·
Jesús Ruiz-Aragón
, Ray Gani
, et al.
·
Human Vaccines & Immunotherapeutics
PDF
Pin86 Clinical and Economic Outcomes Associated With Varying Coverage of Varicella Vaccination Strategies in Switzerland
2019
·
U. Heininger
, L. Wolfson
, et al.
·
Value in Health
PDF
Prm57 - Assessments of Economic Value Using Five Different Oncology Value Frameworks (asco, Esmo, Nccn, Mskcc, Icer)
2018
·
A Ambavane
, G Meier
, et al.
·
Value in Health
Pin111 - Impact of Variation in Influenza Vaccination Schedules and Decision-making Criteria on Patient Outcomes in European Countries
2018
·
R. Gani
, R. Chapman
, et al.
·
Value in Health
Assessment Of Health Technology Appraisals To Identify Key Drivers For Reimbursement Of Oncology Drugs With Only Phase 2 Clinical Data
2017
·
A Duran
, R Morlock
, et al.
·
Value in Health
The Global Burden Of Gastric (GC) And Gastroesophageal Junction (GEJC) Cancers
2017
·
R Morlock
, A Duran
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
28
Citation count:
411
H-index:
10
I10-index:
11
Year
Topic
Type
